Cookie Policy
Find out more about:
Latest News
Registry open for expressions of interest on new biosimilar pharmacovigilance study
The IBD Registry is inviting IBD clinical teams across the UK to participate in a post-marketing safety study of patients using biosimilar Zessly (infliximab). This study is facilitated by the Registry on behalf of Sandoz Ltd, the manufacturer of Zessly. The purpose...
read moreRegistry-based audit of biological therapies in IBD unveiled at BSG2019 meeting
The IBD Registry is delighted a presentation prepared by the Registry’s Analytics Hub at the University of Liverpool featured in the British Society of Gastroenterology Annual Meeting in Glasgow. The Audit of biological therapy for IBD - Shawihdi et al Poster BSG 2019...
read moreNew IBD Standards “a catalyst in building high quality care for patients”
The IBD Registry says the launch of the new IBD Standards, the first for six years, at the BSG Annual meeting in Glasgow today, Thursday, 20th June, will provide a catalyst to drive quality in inflammatory bowel disease (IBD). The IBD Standards, produced by IBD UK, an...
read moreCould your IBD service improve?
Continuing its mission to improve the care that people with IBD receive, the Royal College of Physicians is offering IBD teams an opportunity to participate in a new quality improvement collaborative, consisting of three 1-day learning sessions and supported action...
read moreIBD Registry has a new home
Following the establishment of IBD Registry Limited as an independent not-for-profit company, we have moved offices to: The IBD Registry The Ebbisham Centre 6-7 Derby Square EPSOM KT19 8AG Telephone (unchanged): 020 393 3969 Contact (unchanged):...
read more